國(guó)際新聞精選周四（2017年2月9日）

2017年2月9日 | Filed under: | Posted by: 編輯 D

Buying growth is a tricky choice for Gilead

Gilead Sciences is in a strategic quandary. Acknowledging its sales will shrink in 2017 because of diminishing hepatitis C patient numbers, the group sees no choice but to pursue acquisitions to grow its top line.

The trouble is that it will take a big target with marketed or very late stage assets in order to shift the revenue picture meaningfully, and there are few targets out there that fit the bill. The perils of Teva and Perrigo show how aggressive M&A pursued under pressure can cause investor and executive ructions – and Gilead’s business development record is not unblemished.【閱讀全文】

Swedish drug firm Oncopeptides announces Stockholm IPO

Sweden's Oncopeptides AB said on Wednesday it would list its shares on Nasdaq Stockholm, raising capital for the continued development of its cancer treatment drug Ygalo.

* Says has together with HealthCap and Industrifonden decided, in order to further the company's continued development of its product candidate Ygalo, to carry out a broadening of its shareholder base through a new share issue of 650 million crowns ($73 million).【閱讀全文】

Merrimack employee accused of leaking clinical trial data

Authorities have arrested Merrimack Pharmaceuticals’ director of statistical programming. The case alleges that Songjiang Wang leaked positive results for three different Merrimack clinical trials to an employee of Akebia Therapeutics, who, in turn, shared tips about a study run by his company, Reuters reports.【閱讀全文】

US nod for Amgen’s Parsabiv

Amgen's Parsabiv has now been cleared for use in the US to treat secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis, after it was initially rejected by the US Food and Drug Administration in October last year.

sHPT is a common, serious and often progressive condition among patients with chronic kidney disease CKD, that develops in response to declining kidney function, when the parathyroid (PTH) glands increase the production of thyroid to maintain normal levels of calcium and phosphorus.【閱讀全文】

The next PARP buyout? Tesaro shares surge on latest buzz about a buyout

The PARP wars may be about ready to inspire some fresh M&A activity.

In the wake of Pfizer’s big $14 billion acquisition of Medivation last fall, which included the PARP drug talazoparib, sources are telling Reuters that Tesaro $TSRO has been fielding some incoming queries about a buyout. And with its PARP drug niraparib under review at the FDA, Tesaro has become one of the most frequently cited takeover targets in biotech, where promising late-stage assets can be hard to find.【閱讀全文】

Why Panera Bread, Tesaro, and Universal Corp. Jumped Today

The stock market was narrowly mixed on Wednesday, with the Dow Jones Industrials losing ground but the S&P 500 and Nasdaq Composite posting modest gains on the day. Earnings season has had positive effects on some stocks and negative ones on others, but the general uncertainty in the political realm and its potential impact on future economic growth continues to hold the market back from pushing further toward record-high territory. Nevertheless, some stocks did quite well on Wednesday, and Panera Bread (NASDAQ:PNRA), Tesaro (NASDAQ:TSRO), and Universal Corp. (NYSE:UVV) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.【閱讀全文】

Sanofi, Regeneron win a crucial stay of execution on Praluent

Sanofi and Regeneron’s Praluent gets to stay on the market while the partners fight another day in court for the PCSK9 franchise.

Regeneron $REGN announced just after the market closed on Wednesday that the US Court of Appeals had granted a stay of a controversial decision in early January that Praluent violated Amgen’s patents on the rival PCSK9 cholesterol drug Repatha, warranting its removal from the market.【閱讀全文】

Bayer, J&J wrap positive PhIII cardio study for Xarelto early, looking to beef up its market

Back in the fall of 2012, its sights set on building a blockbuster flagship drug out of its anticoagulant Xarelto, Bayer and its partners at J&J set out to do a massive study to see if the drug could help prevent major cardiovascular events like stroke, myocardial infarction and death in high risk patients with coronary artery disease or peripheral artery disease.

Today, a little more than 4 years and 27,000-plus patients later, investigators say that they hit the primary endpoint well ahead of schedule. Now they’re ending the trial early and launching an extension study where they will continue to dose patients.【閱讀全文】

美中藥源原創(chuàng)文章，轉(zhuǎn)載注明出處并添加超鏈接，商業(yè)用途需經(jīng)書面授權(quán)。
★更多深度解析訪問《美中藥源》~

★ 請(qǐng)關(guān)注《美中藥源》微信公眾號(hào) ★